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Background/aim: Tumor necrosis factor-alfa (TNF-a) antagonists are extensively utilized in the treatment of inflammatory rheumatic
diseases and also shown to be effective in Behçet’s disease (BD) patients with major organ involvement. In this study, we aimed to reevaluate the incidence of tuberculosis (TB) infection after anti-TNFa treatments and to reveal the risk of TB in BD.
Methods: Data of patients who received anti-TNFa treatment between 2005 and 2018 were assessed retrospectively. Demographic
features, TNF-a antagonist type/treatment time, tuberculosis skin test (TST) and QuantiFERON results, isoniazid prophylaxis status,
and concomitant corticosteroid (CS) treatments were collected.
Results: A total of 1277 (male/female = 597/680; median age = 49 years) patients were treated with TNF-a antagonist for a median
of 33 months (Q1:12, Q3:62). Thirteen (1%) patients developed TB during the follow-up period. Within 13 TB-positive patients, 7 of
them had pulmonary, and 7 had extrapulmonary TB. Although, the median time of (month) TNF-a antagonist treatment was higher
in TB-positive patients than negative ones, the difference was not statistically significant (48 and 33 months, respectively, p = 0.47).
Similarly, TB-positive patients were treated with CSs more than TB-negative patients (80% vs. 60%). Time from the initiation of TNF-a
antagonist treatment to the diagnosis of TB had a median of 40 months (Q1-Q3: 22-56). There was a statistically significant increase
of TB development in BD patients than non-BD patients after TNF-a antagonists (7.5% vs. 0.8%, respectively, p = 0.007). When we
combined our patients with the other series from Turkey, among 12928 patients who received TNF-a antagonists, TB was positive in 12
(3.9%) of 305 BD patients compared to 112 (0.9%) of 12623 non-BD patients (p < 0.00001).
Conclusion: Our results suggest a higher frequency of TB infections in BD patients with TNF-a antagonists. As biologic agents are
increasingly used for major organ involvement in current practice for BD, screening mechanisms should be carefully implemented.
Key words: Behçet’s disease, TNF-a antagonists, tuberculosis

1. Introduction
Tumor necrosis factor-alfa (TNF-a) antagonists are
extensively utilized in the treatment of inflammatory
rheumatic diseases such as rheumatoid arthritis (RA)
and ankylosing spondylitis (AS). In recent years,
experience with these agents has also increased in other
immune rheumatological diseases. In Behçet’s disease
(BD), a multisystemic inflammatory disorder, TNF-a
antagonists are also shown to be effective in patients with
major organ involvement, refractory to conventional
immunosuppressives (IS) [1].
The risk of infections is shown to be increased with the
use of TNF-a antagonists as a significant side effect [2].

The enhanced risk of mycobacterial infections is especially
important in countries with still an elevated prevalence
of tuberculosis (TB). In a multicenter large cohort from
Turkey, it was previously observed that patients with BD
are more likely to develop TB after anti-TNFa treatments
compared to other rheumatic diseases [3]. The underlying
mechanism of this observation may be related to factors
unique to BD, such as genetics, immune mechanisms, or
socio-economic status, as well as concomitant treatment
with high dose corticosteroid (CS) and immunosuppressive
therapies [4,5].
In this study, we aimed to re-evaluate the incidence
of TB infection after anti-TNFa treatments for rheumatic
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diseases and to reveal the risk of TB according to the
rheumatologic diagnosis, particularly BD. Factors
associated with this risk are also assessed.
2. Methods
2.1. Patients and data collection
The data of 1277 patients who received TNF-a antagonists
between 2005 and 2018 at Marmara University, School of
Medicine, Rheumatology Outpatient Clinics, were assessed
retrospectively. Patients had to have an inflammatory
rheumatic disease treated with one of the TNF-a antagonists
(Adalimumab, Infliximab, Etanercept, Golimumab, and
Certolizumab Pegol) to be included in the study. Followup data were collected from standard patient report forms
and medical chart reviews: demographic features, TNF-a
antagonist type and treatment time, tuberculosis skin
test (TST) (positive/negative) or QuantiFERON results,
isoniazid prophylaxis status, concomitant CS treatment
(yes/no). For TB patients, time until TB development and
organ involvement type were also recorded.
2.2. Tuberculosis (TB) screening
Patients were screened for TB before and during the
TNF-a antagonist treatments according to the Consensus
Report on using TNF-a antagonists endorsed by the
Rheumatology Society of Turkey [6]. Before starting
TNF-a antagonists, patients were evaluated for TB by a
questionnaire for the presence of prior TB infection or
treatment with antituberculosis drugs and a history of
contact with a tuberculosis-infected case. Additionally,
patients were evaluated for the occurrence of TB signs
and symptoms with a physical examination. At the same
time, patients underwent TST or QuantiFERON test
depending on the availability and Chest radiograph. If the
TST result is ≥ 5mm or QuantiFERON test was positive,
isoniazid (INH) prophylaxis 300 mg/day for nine months
was started. In case of a suspicious finding for latent TB
in the chest radiograph or in physical examination and
anamnesis, INH prophylaxis was decided with a chest
disease or infectious disease specialist, even if screening
tests were negative. Patients were followed up every 3–6
months for the development of pulmonary or extrapulmonary TB with symptom inquiry and physical
examination. Chest radiographs were also repeated once a
year. In the case of suspected TB infection during followup, an appropriate evaluation was made.
2.3. Statistics
Means of continuous variables and standard deviation
when the data were distributed normally were calculated.
Medians and first to third quartile intervals were calculated
when data that did not have a normal distribution.
Group differences for dependent categorical variables
were analyzed with the Chi-square or Fishers’ exact test.
Continuous variables were compared with student t-test or
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Mann–Whitney U when data were skewed. A two-tailed
p-value < 0.05 was considered significant.
3. Results
3.1. Patient demographics
A total of 1277 (male/female = 597/680; median age = 49
years) patients were treated with TNF-a antagonist for a
median of 33 months (Q1:12, Q3:62). During this period,
1560 different TNF-a antagonist prescriptions were
started, Etanercept (n = 509, 33%) and Adalimumab (n =
509, 33 %) were the most frequently selected. The most
common diagnosis were AS (n = 644; 51%) and RA (n =
477; 38%), respectively. Either TST or QuantiFERON tests
were positive in 823 (65%) patients, and the rate of patients
that used INH prophylaxis (872, 69%) was slightly more
than test positivity. CS treatment data were collected in
795 patients as received/not received. Within this group,
38% of the patients received CS at any time during the
follow-up period. The characteristics of all patients in the
study are summarized in Table 1.
3.2. Patient characteristics with and without tuberculosis
(TB)
Among 1277 patients, 13 (1%) of them developed TB
during the follow-up period. While the median age of
TB-positive and negative patients was similar (50 and
49 years, respectively), male presence was higher in TBpositive patients (76% vs. 24%). TST and/or QuantiFERON
positivity and INH usage rates were comparable between
the two groups. Although, the median time of (month)
TNF-a antagonist treatment was higher in TB-positive
patients than negative ones, the difference was not
statistically significant (48 and 33 months, respectively, p =
0.47). Similarly, TB-positive patients were treated with CS
more than TB-negatives (80 % vs. 60 %). The comparison of
patients with and without TB is summarized in Table 1. All
percentages are given based on the total number of patients
with and without TB within the columns in Table 1.
Within 13 TB-positive patients, 6 of them had
pulmonary, 6 had extra-pulmonary TB and 1 had both.
Time from the initiation of TNF-a antagonist treatment to
the diagnosis of TB had a median of 40 months (Q1-Q3:
22-56). At the time of TB diagnosis, all 13 patients were
on anti-TNFa treatments (4 Etanercept, 5 Adalimumab,
2 Infliximab, and 2 Certolizumab Pegol). Due to disease
activity, Certolizumab Pegol and Etanercept were started
again after TB treatment for two patients with AS diagnosis.
According to the underlying disease, TB was more
frequent in the AS group (n = 5, 0.7%) compared to the
other diseases, but patients with BD (n = 3, 8.1%) had
the highest rate for TB (Table 2). There was a statistically
significant increase of TB development in BD patients
than non-BD patients after TNF-a antagonists (7.5% vs.
0.8%, respectively, p = 0.007). When we combined our
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Table 1. Characteristics of the patients treated with anti-TNF-α antagonists.
All patients
(n = 1277)

Patients without TB
(n = 1264)
49
(39–58)

Patients with TB
(n = 13)

p*

50
(41–61)

0.514

Age median (Q1-Q3), years

49
(39–58)

Male

597 (47)

587 (46.4)

10 (77)

0.046

TST and/or QuantiFERON Positivity

823 (65)

815 (65)

8 (61)

0.530

INH prophylaxis

875/1268 (69)

867/1255 (69)

8/13 (61)

0.556

Corticosteroid treatment (at any time)

480/797 (60)

472/785 (60)

8/10 (80)

0.330

Anti-TNFa treatment time median (Q1-Q3) (month)

33
(12–62)

33
(12–62)

48
(22–80)

0.470

Etanercept

509 (40)

501 (40)

8 (61)

0.153

Adalimumab

509 (40)

504 (40)

5 (38)

1.000

Infliximab

380 (30)

375 (30)

5 (38)

0.544

Certolizumab

84 (7)

81 (6)

3 (23)

0.049

Golimumab

78 (6)

78 (6)

0

1.000

Rheumatoid arthritis

479 (38)

475 (38)

4 (30)

0.777

Ankylosing spondylitis

648 (51)

643 (51)

5 (38)

0.415

Psoriatic arthritis

96 (8)

95 (8)

1 (8)

1.000

Behçet’s disease

40 (3)

37 (3)

3 (23)

0.007

Takayasu’s arteritis

14 (1)

14 (1)

0

1.000

Anti-TNFa treatment

Inflammatory disease

Except where indicated otherwise, values are the number/total number (percent) of patients.
TNF: tumor necrosis factor; TB: tuberculosis; TST: tuberculosis skin test; INH: isoniazid.
*Comparison of patients with and without TB.

Table 2. The frequency of TB development according to the underlying disease.
Disease

Patients with TB
(n)

Patients without TB
(n)

%

Rheumatoid arthritis

4

475

0.8

Ankylosing spondylitis

5

643

0.7

Psoriatic arthritis

1

95

0.1

Behçet’s disease

3

37

8.1

Takayasu’s arteritis

0

14

-

patients with the other series from Turkey, among 12928
patients who received TNF-a antagonists, TB was positive
in 12 (3.9%) of 305 BD patients compared to 112 (0.9%)
of 12623 non-BD patients (p < 0.00001). A summary of
all studies published from Turkey, which reported the TB
incidence after TNF-a antagonists and comparison with
the present study is given in Table 3.

3.3. Comparison of BD patients with and without
tuberculosis
Among 40 patients with BD, TB-positive patients (n = 3)
were all male and had a slightly younger mean age than
TB-negatives (34.6 vs. 39 years, respectively, p = 0.456). All
TB-positive patients with BD used INH prophylaxis and
had a positive TST/QuantiFERON. Median time (month)
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Table 3. Studies comparing tuberculosis risk in Behçet’s disease to other inflammatory diseases in the published literature.
Börekçi et al., 2015
Total number of patients treated
with TNF-α antagonists (n)
1964

Kisacik et al., 2016

Çağatay et al.,
Current study
2017

7768

1887

1277

Age years
(mean ± SD)

39.7 ± 13.9

43.4 ± 13.6

42.41 ± 12.71 48.7 ± 13.2

Male/Female
(n)

1009/955

3673/4095

907/980

597/680

TST/ QuantiFERON positivity,
n (%)

1162 (59)

4243 (54.6)

1127 (67.4)

823 (65)

INH prophylaxis
n (%)

1250 (63.6)

5704 (73.4)

NR

872 (69)

Time from initiation of TNF-a
antagonist treatment to the
diagnosis of TB

IFX: 13 months
mean ± SD:
(range 1–96),
26.8 ± 17.1 months
ADA: 13 months (range 3–36),
(range 1–60, median 26.5)
ETN: 7 months (range 4–60)

mean ± SD:
25.7 ± 19.4

median: 40 months
(Q1-Q3: 22–56)

TB positivity, n (%)
Behçet’s disease
Other diseases

3/83 (3.6)
13/1881 (0.7)

5/129 (4)
68/7639 (0.8)

1/53 (1.8)
3/40 (7.5)
21/1866 (1.1) 10/1237 (0.8)

TNF: tumor necrosis factor; TB: tuberculosis; TST: tuberculosis skin test; INH: isoniazid; NR: not reported; IFX: infliximab; ADA:
adalimumab; ETN: etanercept; SD: standard deviation.

of TNF-a antagonist and CS treatment rates were also
slightly higher in TB-positive than TB negative patients
with BD [(20 months vs 16 months, respectively, p = 0.939)
and (3/3 100% vs 29/33 88%, respectively, p = 0.522).
4. Discussion
This study confirmed the increased risk of TB after antiTNFa treatments and suggested that this increased risk
might be greater in BD compared to other rheumatic
disorders.
TNF-a has an important role, particularly in the defense
against mycobacteria and is essential for the maintenance
of granuloma formation [7]. Other key functions of TNF-a
include regulation of apoptosis, release of cytokines from
activating macrophages, and effects on the formation of
nitric oxide and the leucocyte movement [8]. Increased
TB frequency after anti-TNFa treatments has been
reported from large registries [9–12]. This increased risk
has been reported more prominently for monoclonal
antibodies Adalimumab and Infliximab compared to
soluble receptors such as Etanercept. Although screening
and prophylaxis improved much in recent years, TNF-a
inhibition may affect some countries more seriously, such
as Turkey, with a not too-low (22/100 000) incidence of
TB. In a multicenter cohort study from Turkey, Kisacik
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et al. reported 73 TB-positive cases within 7768 patients
treated with TNF-a antagonists [3]. In other publications
from Turkey, Çağatay et al. reported 22 TB-positive cases
within 1887 patients and Börekçi et al. 16 TB-positive
cases within 1964 patients after TNF-a antagonists [13,14].
Our TB prevalence was similar to these other studies from
Turkey (0.7-1.1%).
As both BD and TB infection are common diseases in
Turkey, TB data among TNF-a antagonist treated patients
deserve separate analysis. Apart from Turkey, a few case
reports have been published in the literature on BD and
TB coexistence [15-18]. In the series from Turkey, Kisacik
et al. showed that TB development rate was higher in BD
compared to other rheumatic diseases (5/129, 4%). TB
rate was also reported higher in BD than other diseases
by Çağatay et al. (1/53, 1.8%). Börekçi et al. also found
BD to be associated with the development of TB infection
in multivariate analysis (3/83, 3.6%, p = 0.003). We
documented even a higher rate of TB among BD patients
than other Turkish cohorts (3/40, 7.5 %). As a whole, the
more frequent use of TNF-a antagonists in recent years
in patients with major organ involvement, also suggested
by the recent EULAR recommendations, requires more
research on the infectious side-effects of anti-TNFa
treatments in BD (1).
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Some underlying mechanisms may be suggested
for this higher TB prevalence after anti-TNFa exposure
in BD. Patients with major-organ BD are generally
males at a younger age and usually actively participate
in the workforce, which may cause more contact with
mycobacteria compared to other patient groups. The fact
that BD patients have lower socio-economic status may be
another reason [4,5]. Higher CS doses (0.5-1 mg/kg/day),
especially used in the initial use of TNF-a antagonists, to
suppress major organ damage such as vision loss or arterial
complications may also contribute to the development of
TB. Immune mechanisms leading to BD activation, such
as augmented innate immunity and male sex-related
effects, might also predispose BD patients to mycobacterial
infections. Finally, some HLA genes are associated with
tuberculosis [19–22]. Some of these genetic associations
are also shown in BD [23,24]. More studies are needed to
clarify these mechanisms.

Our study has some limitations. Data for the
concomitant use, especially dosing of CS treatments and
additional immunosuppressives, are not collected in our
group. Also, we do not formally assess the socio-economic
status data of our patients.
In conclusion, our results suggest a higher frequency
of TB infections in BD patients with TNF-a antagonists.
As biologic agents are increasingly used for major organ
involvement in current practice for BD, screening
mechanisms should be carefully implemented and
followed.
Informed consent
Study protocol was approved by Marmara University
Local Ethics Committee (approval number: 09.2020.978)
and the study was performed according to the Declaration
of Helsinki. Patient informed consent was not required for
being a retrospective data collection.
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